


FSLLRY-NH2 TFA

Cat. No.:	HY-P1260A
Molecular Formula:	C ₄₁ H ₆₁ F ₃ N ₁₀ O ₁₀
Molecular Weight:	910.98
Sequence:	Phe-Ser-Leu-Leu-Arg-Tyr-NH2
Sequence Shortening:	FSLLRY-NH2
Target:	Protease Activated Receptor (PAR)
Pathway:	GPCR/G Protein
Storage:	Sealed storage, away from moisture
	Powder -80°C 2 years
	-20°C 1 year

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (109.77 mM; Need ultrasonic)				
	H ₂ O : 1.43 mg/mL (1.57 mM; Need ultrasonic)				
	Preparing Stock Solutions	<div>Solvent Concentration</div> <div>Mass</div>	1 mg	5 mg	10 mg
		1 mM	1.0977 mL	5.4886 mL	10.9772 mL
		5 mM	0.2195 mL	1.0977 mL	2.1954 mL
10 mM		0.1098 mL	0.5489 mL	1.0977 mL	
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	1. Add each solvent one by one: PBS Solubility: 8.33 mg/mL (9.14 mM); Clear solution; Need ultrasonic				
	2. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (2.74 mM); Clear solution				
	3. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (2.74 mM); Clear solution				
	4. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (2.74 mM); Clear solution				

BIOLOGICAL ACTIVITY

Description	FSLLRY-NH2 TFA is a protease-activated receptor 2 (PAR2) inhibitor ^[1] .
IC ₅₀ & Target	PAR2

In Vivo

Treatment with FSLLRY-NH2 (50 µg per rat administered intranasally at 1 hour postresuscitation) significantly improves neurological outcome and reduces the number of degenerating hippocampal neurons after ACA (asphyxial CA)^[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- BMC Musculoskelet Disord. 2022 May 30;23(1):514.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Umut Ocak, et al. FSLLRY-NH2 Improves Neurological Outcome After Cardiac Arrest in Rats. Turk Neurosurg. 2020;30(2):244-251.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA